Analysts expect ChemoCentryx, Inc. (NASDAQ:CCXI) to report $-0.28 EPS on March, 8.They anticipate $1.08 EPS change or 135.00% from last quarter’s $0.8 EPS. After having $-0.22 EPS previously, ChemoCentryx, Inc.’s analysts see 27.27% EPS growth. The stock decreased 1.92% or $0.21 during the last trading session, reaching $10.75. About 93,809 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 69.59% since February 19, 2018 and is uptrending. It has outperformed by 69.59% the S&P500. Some Historical CCXI News: 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA
Hollyfrontier Corp (HFC) investors sentiment decreased to 0.96 in Q3 2018. It’s down -0.23, from 1.19 in 2018Q2. The ratio worsened, as 214 hedge funds started new and increased equity positions, while 223 sold and reduced stakes in Hollyfrontier Corp. The hedge funds in our database now have: 138.53 million shares, down from 148.93 million shares in 2018Q2. Also, the number of hedge funds holding Hollyfrontier Corp in top ten equity positions decreased from 8 to 5 for a decrease of 3. Sold All: 43 Reduced: 180 Increased: 132 New Position: 82.
Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. ChemoCentryx had 4 analyst reports since September 7, 2018 according to SRatingsIntel. The rating was initiated by Leerink Swann with “Buy” on Thursday, February 14. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) earned “Buy” rating by Canaccord Genuity on Monday, November 12.
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $543.15 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It has a 43.52 P/E ratio. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe Crohn’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.
Since October 16, 2018, it had 0 insider purchases, and 8 sales for $87.64 million activity. Another trade for 36,762 shares valued at $447,092 was sold by Schall Thomas J.. Cappel Markus J. also sold $74,079 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) on Thursday, January 10. 37,893 ChemoCentryx, Inc. (NASDAQ:CCXI) shares with value of $457,747 were sold by KANAYA SUSAN M. Another trade for 7.34M shares valued at $85.85M was made by GLAXOSMITHKLINE PLC on Tuesday, October 16.
Investors sentiment decreased to 0.98 in Q3 2018. Its down 0.61, from 1.59 in 2018Q2. It worsened, as 14 investors sold ChemoCentryx, Inc. shares while 29 reduced holdings. 13 funds opened positions while 29 raised stakes. 26.80 million shares or 1.64% more from 26.37 million shares in 2018Q2 were reported. Wasatch Advsr Inc, a Utah-based fund reported 2.39M shares. Qs Invsts Ltd Liability Co owns 643 shares. Arrowstreet Capital Limited Partnership owns 210,762 shares. Cadence Cap Management Ltd accumulated 95,344 shares. Tiaa Cref Management Limited Liability accumulated 331,336 shares or 0% of the stock. Barclays Plc holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 15,304 shares. Royal Bankshares Of Canada has invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Farallon Limited Liability holds 0.09% or 1.15M shares. J Goldman And Co L P has 32,500 shares. Alps Advsrs accumulated 0.01% or 130,929 shares. Sectoral Asset Mgmt Incorporated reported 17,811 shares. Moreover, Schwab Charles Investment Mgmt Incorporated has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 49,177 shares. Fosun Ltd invested in 159,050 shares. California State Teachers Retirement Sys stated it has 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Meeder Asset Mngmt owns 3,118 shares.
More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Seekingalpha.com which released: “Piper likes ChemoCentryx in premarket analyst action – Seeking Alpha” on February 11, 2019, also Seekingalpha.com with their article: “Chemocentryx secures $20M capital raise – Seeking Alpha” published on January 31, 2019, Seekingalpha.com published: “ChemoCentryx withdraws conditional approval application for avacopan in Europe – Seeking Alpha” on January 24, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Seekingalpha.com and their article: “ChemoCentryx terminates previously announced common stock offering – Seeking Alpha” published on September 28, 2018 as well as Globenewswire.com‘s news article titled: “ChemoCentryx Announces Proposed Public Offering of Common Stock – GlobeNewswire” with publication date: September 26, 2018.
HollyFrontier Corporation operates as an independent petroleum refiner in the United States. The company has market cap of $9.96 billion. The firm operates through two divisions, Refining and HEP. It has a 6.97 P/E ratio. It primarily produces high-value refined products, such as gasoline, diesel fuel, jet fuel, specialty lubricant products, and specialty and modified asphalt.
Since January 1, 0001, it had 0 insider buys, and 1 sale for $92,429 activity.
The stock decreased 0.45% or $0.26 during the last trading session, reaching $57.63. About 561,610 shares traded. HollyFrontier Corporation (HFC) has risen 21.25% since February 19, 2018 and is uptrending. It has outperformed by 21.25% the S&P500. Some Historical HFC News: 03/04/2018 – HollyFrontier Corporation First Quarter 2018 Earnings Release and Conference Webcast; 29/05/2018 – HOLLYFRONTIER CORP – ISSUES STATEMENT ON PASSING OF FORMER CHAIRMAN AND CEO, LAMAR NORSWORTHY; 23/04/2018 – Douglas Lane Adds SS&C, Exits Alcoa, Cuts HollyFrontier: 13F; 09/05/2018 – HollyFrontier Corporation Announces Regular Cash Dividend; 03/05/2018 – HollyFrontier Tops Refiner Rally on Biggest-Ever Marathon Merger; 29/03/2018 – DIARY-U.S. refinery operations-Motiva Port Arthur refinery shutting reformer; 26/03/2018 – HOLLYFRONTIER SEES 2018 REFINING & MARKETING CAPEX OF $375 MLN TO $425 MLN – SEC FILING; 02/05/2018 – HOLLYFRONTIER RAN 174K B/D PERMIAN CRUDE IN 1Q; 23/03/2018 – HOLLYFRONTIER – UNIT’S WOODS CROSS REFINERY LOCATED IN UTAH RUNNING AT REDUCED RATES DUE TO A CRUDE UNIT FIRE THAT OCCURRED ON MARCH 12; 02/05/2018 – HOLLYFRONTIER 1Q PRODUCTION 415,260 B/D
Tctc Holdings Llc holds 40.34% of its portfolio in HollyFrontier Corporation for 12.58 million shares. Robertson Opportunity Capital Llc owns 186,500 shares or 7.64% of their US portfolio. Moreover, American Beacon Advisors Inc. has 2.5% invested in the company for 5,262 shares. The New Jersey-based Edgestream Partners L.P. has invested 1.99% in the stock. Cookson Peirce & Co Inc, a Pennsylvania-based fund reported 292,375 shares.
Analysts await HollyFrontier Corporation (NYSE:HFC) to report earnings on February, 20 before the open. They expect $1.71 earnings per share, up 144.29% or $1.01 from last year’s $0.7 per share. HFC’s profit will be $295.53M for 8.43 P/E if the $1.71 EPS becomes a reality. After $1.98 actual earnings per share reported by HollyFrontier Corporation for the previous quarter, Wall Street now forecasts -13.64% negative EPS growth.
More important recent HollyFrontier Corporation (NYSE:HFC) news were published by: Nasdaq.com which released: “Report: Exploring Fundamental Drivers Behind Lattice Semiconductor, Baker Hughes, a GE company, Steel Dynamics, HollyFrontier, Omnicom Group, and Ultra Clean â€” New Horizons, Emerging Trends, and Upcoming Developments – Nasdaq” on January 28, 2019, also Seekingalpha.com published article titled: “Shell, union reach deal to raise refinery worker pay by 11% – Seeking Alpha”, Bizjournals.com published: “Find out how much DFW’s largest companies pay their median employee – Dallas Business Journal” on January 22, 2019. More interesting news about HollyFrontier Corporation (NYSE:HFC) was released by: Businesswire.com and their article: “HollyFrontier Closes Acquisition of Sonneborn – Business Wire” with publication date: February 01, 2019.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.